Products for Research Use Only

Chicken anti Human osteopontin-c (the shortest splice variant of osteopontin)

CAT: 0579-AhOPNcSize: 0.1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0579-AhOPNcSize:0.1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
CAS Number
9007-83-4
UniProt
P10451
Host
Chicken
Species Reactivity
Human
Conjugation
Affinity Purified
Type
Primary Antibodies
Source
A chicken was immunized with a peptide representing the splice junction of osteopontin-c (Ac-SEEKQNAVSC-COOH). After multiple immunizations, eggs were collected and IgY was purified from the egg yolk. The antibody was affinity purified on an osteopontin-c peptide column.
Applications
WB, ELISA
Field of Research
Extracellular matrix
Purification Method
Egg-yolk derived IgY Affinity Purified
Assay Principle
This antibody has been tested in ELISA and a sµggested starting dilution for ELISA analysis is 2 µg/mL. For Western blotting, recommended concentration 1 µg/mL (See image). Optimal working dilutions should be determined for your particular assay conditions.
Concentration
See vial for Concentration
Form
Phosphate buffered saline‚ pH 7,2 with 0,075% sodium azide
Precautions
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving Humans or animals.
References & Citations
1. He B, Mirza M, Weber GF., 2006. An osteopontin splice variant induces anchorage independence in Human breast cancer cells. Oncogene 25:2192–2202._x000D_ 2. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF., 2008. Osteopontin-c is a selective marker of breast cancer. Int J Cancer: 122:2646._x000D_ 3. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ, Arafat HA., 2009. Expression of a prometastatic splice variant of osteopontin, OPNC, in Human pancreatic ductal adenocarcinoma. Surgery 146:232-40._x000D_ 4. Tilli, TM, Thuler LC, Matos, AR, Coutinho-Camillo, CM, Soares, FA, da Silva, EA, Neves, AF, Goulart, LR and ER Gimba. 2011.Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp. Mol. Pathol. 92:13-19._x000D_ 5. Tilli, TM, Mello, KD, Ferreira, LB, Matos, AR, Accioly, MTS, Faria, PAS., Bellahcène, A, Castronovo, V and ER Gimba. 2012. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 72:1688-1699._x000D_ 6. Zhang, MX, Xu YJ, Zhu MC and F. Yan. 2013. Overexpressed Osteopontin-c as a Potential Biomarker for Esophageal Squamous Cell Carcinoma. Asian Pac J Cancer Prev 14: 7315-9_x000D_ 7. T. Martins Tilli, L. Bueon Ferreira and E.R. Pereira Gimba. 2015. Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through P13K/Akt and androgen receptor signaling. Oncol. Lett. 9: 1845-50. _x000D_ 8. Zduniak K., Ziolkowski, P. Ahlin C., Agrawal, A., Blomqvist, C., Fjallskog, M.L., and G.F. Weber. 2015. Nuclear Osteopontin-c is a prognostic breast cancer marker. Br. J. Cancer 112:729-38._x000D_ 9. Zduniak, K, Agrawal, A, Agriwal, S, Hossain, MM, Ziolkowski, P and GF Weber, 2016. Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer 16:441.
Shipping Conditions
Ambient Temperature
Storage Conditions
Product should be stored at -20ºC; Aliquot to avoid freeze/thaw cycles